Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C A Jackson

Showing results (121-130 of 124) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 124 results.
British Journal of Clinical Pharmacology|May 7, 2021
Oral paclitaxel with encequidar compared to intravenous paclitaxel in patients with advanced cancer: A randomised crossover pharmacokinetic studyChristopher G C A Jackson, Tak Hung, Eva Segelov, et al.
Therapeutic Advances in Medical Oncology|July 26, 2023
Oral paclitaxel and encequidar in patients with breast cancer: a pharmacokinetic, safety, and antitumor activity studyMing-Shen Dai, Ta-Chung Chao, Chang-Fang Chiu, et al.
The Lancet. Oncology|April 9, 2022
Risk factors and prognostic implications of diagnosis of cancer within 30 days after an emergency hospital admission (emergency presentation): an International Cancer Benchmarking Partnership (ICBP) population-based studySean McPhail, Ruth Swann, Shane A Johnson, et al.
The Lancet. Oncology|June 1, 2026
International disruptions to cancer diagnosis and stage at presentation during the COVID-19 pandemic in 2020: an International Cancer Benchmarking Partnership (ICBP) population-based studyEileen Morgan, Aude Bardot, Oliver Langselius, et al.
Pageof 13

Showing results (121-130 of 124) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 124 results.
British Journal of Clinical Pharmacology|May 7, 2021
Oral paclitaxel with encequidar compared to intravenous paclitaxel in patients with advanced cancer: A randomised crossover pharmacokinetic studyChristopher G C A Jackson, Tak Hung, Eva Segelov, et al.
Therapeutic Advances in Medical Oncology|July 26, 2023
Oral paclitaxel and encequidar in patients with breast cancer: a pharmacokinetic, safety, and antitumor activity studyMing-Shen Dai, Ta-Chung Chao, Chang-Fang Chiu, et al.
The Lancet. Oncology|April 9, 2022
Risk factors and prognostic implications of diagnosis of cancer within 30 days after an emergency hospital admission (emergency presentation): an International Cancer Benchmarking Partnership (ICBP) population-based studySean McPhail, Ruth Swann, Shane A Johnson, et al.
The Lancet. Oncology|June 1, 2026
International disruptions to cancer diagnosis and stage at presentation during the COVID-19 pandemic in 2020: an International Cancer Benchmarking Partnership (ICBP) population-based studyEileen Morgan, Aude Bardot, Oliver Langselius, et al.
Pageof 13